4536 — SANTEN PHARMACEUTICAL Share News
0.000.00%
Last trade - 00:00- ¥558bn
- ¥537bn
- ¥292bn
Table: Santen Pharm -2018/19 group results (IFRS)
Brief: Santen Pharmaceutical To Buy Back Up To 2 Percent Of Its Shares Worth 14 Billion Yen Through March 22
Table: Santen Pharm -9-MTH group results (IFRS)
Table: Santen Pharm -6-MTH group results (IFRS)
Brief: Santen Announces Initiation Of Phase 3 Clinical Development Program
Brief: PeptiDream announces drug discovery and development agreement with Santen Pharmaceutical
Table: Santen Pharm -Q1 group results (IFRS)
Table: Santen Pharm -2017/18 group results (IFRS)
Table: Santen Pharm -2017/18 parent results
Table: Santen Pharm -9-MTH group results (IFRS)
Table: Santen Pharm -6-MTH group results (IFRS)
Table: Santen Pharm -Q1 group results (IFRS)
Brief: Santen and Tracon announce initiation of a phase 2a study of drug for the treatment of wet age-related macular degeneration
Brief: Aequus Pharmaceuticals enters into agreement with Santen Pharmaceutical's unit
Table: Santen Pharm -2016/17 parent results
Table: Santen Pharm -2016/17 group results (IFRS)
Table: Santen Pharm -9-MTH group results (IFRS)
Brief: Santen Pharmaceutical to retire treasury shares
Brief: Santen Pharmaceutical repurchases shares at 12.31 bln yen